ProBio, a subsidiary of GenScript Biotech Corporation, has opened its flagship Cell and Gene Therapy Center of Excellence at the Princeton West Innovation Campus in Hopewell, New Jersey. The 128,000 square foot GMP facility is dedicated to manufacturing high-quality plasmid DNA and viral vectors, including adeno-associated virus (AAV) and lentiviral vector (LVV) platforms. This new facility is a significant step in ProBio's mission to accelerate the delivery of transformative medicines. During the ribbon-cutting ceremony, leaders emphasized the strategic importance of this state-of-the-art, fully integrated Contract Development and Manufacturing Organization in enhancing New Jersey's role as a leader in the cell and gene therapy sector. The event included a keynote address by Donavon Decker, a pioneer in gene therapy for muscular dystrophy, who highlighted the impact of such facilities in translating scientific breakthroughs into tangible patient outcomes.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.